Novo Nordisk A/S (NYSE:NVO) Shares Sold by Clean Yield Group

Clean Yield Group lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,876 shares of the company’s stock after selling 510 shares during the period. Clean Yield Group’s holdings in Novo Nordisk A/S were worth $2,914,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVO. Cooper Financial Group increased its position in Novo Nordisk A/S by 5.7% in the 4th quarter. Cooper Financial Group now owns 11,072 shares of the company’s stock valued at $952,000 after acquiring an additional 593 shares during the period. Wedmont Private Capital raised its stake in shares of Novo Nordisk A/S by 3.0% during the fourth quarter. Wedmont Private Capital now owns 11,450 shares of the company’s stock valued at $988,000 after purchasing an additional 330 shares in the last quarter. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter worth about $4,066,000. Westmount Partners LLC increased its stake in Novo Nordisk A/S by 13.1% during the 4th quarter. Westmount Partners LLC now owns 2,405 shares of the company’s stock valued at $207,000 after buying an additional 279 shares during the period. Finally, Salem Investment Counselors Inc. raised its position in shares of Novo Nordisk A/S by 2.3% during the 4th quarter. Salem Investment Counselors Inc. now owns 21,926 shares of the company’s stock worth $1,886,000 after buying an additional 491 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 2.2 %

NYSE:NVO traded down $1.93 during trading hours on Monday, hitting $84.33. 5,607,502 shares of the stock traded hands, compared to its average volume of 7,144,377. The firm has a market cap of $378.43 billion, a price-to-earnings ratio of 27.29, a PEG ratio of 1.37 and a beta of 0.45. The firm has a 50 day moving average price of $100.35 and a 200 day moving average price of $119.04. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BMO Capital Markets lowered their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.